Vertran, 24 mg tablets 60 pcs

An agonist of H1-histamine receptors of the inner ear vessels and an antagonist of H3-histamine receptors of the vestibular nuclei of the central nervous system (CNS).

It has no effect on H2-histamine receptors, which improves blood circulation in the vascular band of the inner ear due to the relaxing effect on the pre-capillary sphincters of the cochlea and labyrinth.

Relieves symptoms of Meniere’s syndrome and vertigo.

Indications

Cerebral Circulatory Disorder, Dizziness, Meniere’s DiseaseMeniere’s Syndrome, characterized by the following main symptoms:
– vertigo (accompanied by nausea/vomiting)
– hearing loss
– tinnitus
Symptomatic treatment and prevention of vestibular vertigo (vertigo) of various etiologies.

Active ingredient

Betahistine

Interaction

In vivo studies to study the interaction with other drugs have not been conducted. Based on the in vitro data, it can be assumed that there is no inhibition of cytochrome P450 isoenzyme activity.

When concomitant use with H1-histamine receptor blockers the therapeutic effect of betahistine may decrease.

Directions for use

Orally, with meals.

The dose of the drug is:
Tablets 24 mg: 1 tablet 2 times a day.

Maximal daily dose is 48 mg.

The dose and duration of treatment should be adjusted individually depending on the patient’s reaction to the treatment.
Improvement is usually observed at the beginning of therapy, but it can also be gradual and appear even after several weeks of treatment. Stable therapeutic effect in some cases is achieved after several months of treatment.

Dose adjustment in elderly patients as well as in patients with renal and/or hepatic impairment is not required.

Special Instructions

Effect on the ability to drive vehicles and mechanisms

According to the results of clinical trials, it is believed that the effect of betahistine on the ability to drive and other mechanisms is absent or insignificant, since the effects potentially affecting this ability have not been found.

Features

When administered orally it is quickly and completely absorbed in the gastrointestinal tract.

Binding to plasma proteins is low (less than 5%). The maximum plasma concentration (Cmax) is reached after 1 hour. When taking the drug with food maximum concentration in blood is lower than on an empty stomach, but total absorption of betahistine is the same in both cases, indicating that food intake only slows absorption of betahistine. Metabolized in the liver with the formation of the inactive metabolite 2-pyridylacetic acid.

Almost completely (90.7%) excreted by the kidneys as a metabolite (2-pyridylacetic acid) within 24 hours. The elimination half-life is 3-4 hours. The elimination rate remains constant, indicating the linearity of the pharmacokinetics of betahistine.

Contraindications

Hypersensitivity to any of the components of the drug. Due to insufficient data on efficacy and safety: pregnancy and lactation; age under 18 years.

With caution
Betahistine should be administered with caution when treating patients with peptic ulcer disease and duodenal ulcer in the anamnesis. Patients with pheochromocytoma and bronchial asthma should be regularly monitored by a physician during treatment.

Side effects

Gastrointestinal tract: often (>1/100 to < 1/10) – nausea and dyspepsia.

Nervous system disorders: often (>1/100 to < 1/10) – headache.

In addition to these effects identified in clinical studies, the following side effects have been reported during post-marketing use and in the scientific literature (the available data are insufficient to estimate their frequency):

Gastrointestinal side effects: moderate disorders such as vomiting, gastrointestinal pain, and bloating. As a rule, these effects disappear if the drug is taken simultaneously with food or after reducing the dose.

Skin and subcutaneous fat: angioedema, urticaria, itching and rash.

Immune system: hypersensitivity reactions, including reported anaphylactic reactions.

Overdose

Symptoms: Mild to moderate symptoms (nausea, drowsiness, abdominal pain) may occur after dosing up to 640 mg. More serious complications (e.g., seizures, cardiopulmonary complications) may be observed when taking higher doses of betahistine, especially in combination with other drugs.

Treatment: symptomatic.

Patients with pheochromocytoma should use the drug under medical supervision.

.

Similarities

Betaserk, Vestibo, Betahistine, Betahistine NW, Tagista